Drug-Induced Rhabdomyolysis Secondary To Lenalidomide

Main Article Content

Himanshu Rathore
Sananjay Singh



Lenalidomide is an immunomodulator imide compound that works through its antitumor, anti-angiogenic, and anti-osteoclastogenic effects. It is increasingly used for a multitude of inflammatory disorders and cancers. Diarrhea, thrombocytopenia, neutropenia, and blood clots are well-established severe side effects of Lenalidomide, but rhabdomyolysis is a rare side effect of the drug. It is difficult to reach this diagnosis because it needs a detailed history of the evolution of symptoms and carefully ruling out other etiologies, especially other drugs. Here we present the case of a 75-year-old female who developed rhabdomyolysis and, subsequently, acute kidney injury after receiving Lenalidomide therapy for multiple myeloma. Discontinuation of the diuretics and the use of isotonic fluids led to a gradual improvement in her condition. Physicians should be aware of this potential rare complication and keep it on the differential when treating patients on Lenalidomide.

Article Details

How to Cite
Rathore, H. and Singh, S. (2023) “Drug-Induced Rhabdomyolysis Secondary To Lenalidomide”, International Journal of Integrated Medical Research, 10(01), pp. 01–03. doi: 10.57181/ijoimr/vol10i01/92.
Case Report
Author Biography

Sananjay Singh, Faculty of Internal Medicine, University of Illinois, Peoria IL, USA

Faculty of Internal Medicine


• Cabral BMI, Edding SN, Portocarrero JP, Lerma EV. Rhabdomyolysis. Dis Mon. 2020;66(8):101015. doi:10.1016/j.disamonth.2020.101015

• Cervellin G, Comelli I, Lippi G. Rhabdomyolysis: historical background, clinical, diagnostic and therapeutic features. Clin Chem Lab Med. 2010;48(6):749-756. doi:10.1515/CCLM.2010.151

• Brancaccio P, Lippi G, Maffulli N. Biochemical markers of muscular damage. Clin Chem Lab Med. 2010;48(6):757-767. doi:10.1515/CCLM.2010.179

• Barrio S, Munawar U, Zhu YX, et al. IKZF1/3 and CRL4CRBN E3 ubiquitin ligase mutations and resistance to immunomodulatory drugs in multiple myeloma. Haematologica. 2020;105(5):e237-e241. doi:10.3324/haematol.2019.217943

• Myelodysplastic syndromes treatment: Revlimid® (lenalidomide). REVLIMID® (lenalidomide) Patient Site. (2021, November 1). Retrieved December 4, 2022, from https://www.revlimid.com/mds

• Kotchetkov R, Masih-Khan E, Chu CM, et al. Secondary primary malignancies during the lenalidomide-dexamethasone regimen in relapsed/refractory multiple myeloma patients. Cancer Med. 2017;6(1):3-11. doi:10.1002/cam4.799

• Shahan JL, Panu LD, Hildebrandt GC. Rhabdomyolysis in a multiple myeloma patient secondary to concurrent treatment with lenalidomide and pravastatin and to lenalidomide alone. Int J Hematol. 2012;96(6):818-819. doi:10.1007/s12185-012-1226-3

• Ema. (2022, December 6). Revlimid. European Medicines Agency. Retrieved December 4, 2022, from https://www.ema.europa.eu/en/medicines/human/EPAR/revlimid

• Gandhi AK, Kang J, Capone L, et al. Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function. Curr Cancer Drug Targets. 2010;10(2):155-167. doi:10.2174/156800910791054239

• November 15, 2022, November 2, 2022, & October 6, 2022. (n.d.). New use for lenalidomidein multiple myeloma. National Cancer Institute. Retrieved December 4, 2022, from https://www.cancer.gov/news-events/cancer-currents-blog/2017/fda-lenalidomide-myeloma-maintenance